Kriya Therapeutics is a biotechnology company developing durable medicines intended to replace repeated treatment for chronic diseases with lasting therapies that may require a single administration. The company aims to make these treatments scalable and accessible to millions of people. Its investigational programs target geographic atrophy, thyroid eye disease, type 1 diabetes, steatotic liver disease, and trigeminal neuralgia; the company also reports research into gene therapy approaches.

Kriya combines research, development, and manufacturing in an integrated product engine, incorporating manufacturing considerations early in drug discovery. Its structured manufacturing dataset, HOPSON™, supports this approach, while artificial intelligence and computational tools are used to learn from experiments, production runs, and other data. Scientists, engineers, and operators work at the company’s campus in Research Triangle Park, North Carolina, with the goal of advancing medicines from discovery toward commercialization.

Kriya describes its therapies as investigational; none has been approved as safe or effective by a regulatory health authority. The company shares updates on its research, medicines, manufacturing capabilities, and career opportunities.